Technical Analysis for KMPH - KemPharm, Inc.

Grade Last Price % Change Price Change
grade B 2.841 0.39% 0.01
KMPH closed down 4.07 percent on Friday, December 7, 2018, on 1.23 times normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical KMPH trend table...

Date Alert Name Type % Chg
Dec 7 50 DMA Support Bullish 0.39%
Dec 7 Overbought Stochastic Strength 0.39%
Dec 7 Upper Bollinger Band Touch Strength 0.39%
Dec 6 20 DMA Support Bullish -3.69%
Dec 6 Crossed Above 50 DMA Bullish -3.69%
Dec 6 New Uptrend Bullish -3.69%
Dec 6 Expansion Pivot Buy Setup Bullish Swing Setup -3.69%
Dec 6 Pocket Pivot Bullish Swing Setup -3.69%
Dec 6 Volume Surge Other -3.69%
Dec 6 Wide Range Bar Range Expansion -3.69%

Older signals for KMPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Is KMPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 4 Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
Dec 3 KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th
Nov 26 What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
Nov 21 Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
Nov 13 KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
Nov 10 Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
Nov 9 KemPharm (KMPH) CEO Travis Mickle on Q3 2018 Results - Earnings Call Transcript
Nov 8 KemPharm reports Q3 results
Nov 8 KemPharm, Inc. Reports Third Quarter 2018 Results
Nov 1 KemPharm to Report Third Quarter 2018 Results
See more KMPH news...
Indicators
Indicator Value
52 Week High 8.4
52 Week Low 2.0
Average Volume 371,208
200-Day Moving Average 4.9733
50-Day Moving Average 2.727
20-Day Moving Average 2.5248
10-Day Moving Average 2.5755
Average True Range 0.2292
ADX 29.88
+DI 21.9539
-DI 16.22
Chandelier Exit (Long, 3 ATRs ) 2.3124
Chandelier Exit (Short, 3 ATRs ) 2.8576
Upper Bollinger Band 2.8343
Lower Bollinger Band 2.2153
Percent B (%b) 0.99
BandWidth 24.516793
MACD Line -0.0007
MACD Signal Line -0.0763
MACD Histogram 0.0756
Fundamentals Value
Market Cap 41.48 Million
Num Shares 14.7 Million
EPS -3.10
Price-to-Earnings (P/E) Ratio -0.91
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.46
Resistance 3 (R3) 3.45 3.22 3.36
Resistance 2 (R2) 3.22 3.06 3.23 3.32
Resistance 1 (R1) 3.03 2.96 2.92 3.04 3.28
Pivot Point 2.80 2.80 2.75 2.81 2.80
Support 1 (S1) 2.61 2.64 2.50 2.62 2.38
Support 2 (S2) 2.38 2.54 2.39 2.34
Support 3 (S3) 2.19 2.38 2.31
Support 4 (S4) 2.20